The Manufacturers Life Insurance Company increased its holdings in Epizyme Inc (NASDAQ:EPZM) by 18.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,451 shares of the biopharmaceutical company’s stock after acquiring an additional 6,005 shares during the period. The Manufacturers Life Insurance Company owned about 0.06% of Epizyme worth $482,000 at the end of the most recent reporting period.
A number of other institutional investors have also made changes to their positions in the stock. Bailard Inc. purchased a new stake in Epizyme in the 4th quarter worth about $251,000. Teacher Retirement System of Texas purchased a new stake in Epizyme in the 4th quarter worth about $202,000. Alps Advisors Inc. lifted its stake in Epizyme by 33.6% in the 4th quarter. Alps Advisors Inc. now owns 76,773 shares of the biopharmaceutical company’s stock worth $964,000 after acquiring an additional 19,301 shares in the last quarter. Jennison Associates LLC lifted its stake in Epizyme by 0.4% in the 4th quarter. Jennison Associates LLC now owns 1,875,528 shares of the biopharmaceutical company’s stock worth $23,538,000 after acquiring an additional 7,867 shares in the last quarter. Finally, Peregrine Capital Management LLC purchased a new stake in Epizyme in the 4th quarter worth about $6,275,000. 85.88% of the stock is owned by hedge funds and other institutional investors.
Epizyme Inc (EPZM) opened at $18.65 on Tuesday. Epizyme Inc has a one year low of $9.30 and a one year high of $21.40.
In related news, COO Matthew Ros sold 72,264 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $16.63, for a total value of $1,201,750.32. Following the transaction, the chief operating officer now directly owns 74,867 shares of the company’s stock, valued at approximately $1,245,038.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 25.20% of the stock is currently owned by company insiders.
Several brokerages recently issued reports on EPZM. BidaskClub raised Epizyme from a “sell” rating to a “hold” rating in a research note on Saturday, January 6th. ValuEngine raised Epizyme from a “sell” rating to a “hold” rating in a research note on Tuesday, February 13th. Roth Capital started coverage on Epizyme in a research note on Thursday, February 1st. They set a “buy” rating and a $24.00 price target for the company. Oppenheimer set a $26.00 price target on Epizyme and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Finally, Zacks Investment Research downgraded Epizyme from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $23.50.
COPYRIGHT VIOLATION NOTICE: “Epizyme Inc (EPZM) Shares Bought by The Manufacturers Life Insurance Company” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2018/03/20/epizyme-inc-epzm-shares-bought-by-the-manufacturers-life-insurance-company.html.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.